Back to Search
JAMES ENGELMAN, M.D.
M.D.
Internal Medicine Physician
NPI: 1518963982Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G50384(CA)
Research & Publications (20)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
PMID 19629070·Nat Rev Cancer·2009
6-review
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
PMID 18325754·Curr Opin Genet Dev·2008
6-review
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
PMID 18483355·Clin Cancer Res·2008
6-review
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
PMID 17463250·Science·2007
7-preclinical
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
PMID 17671156·Clin Cancer Res·2007
6-review
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
PMID 18089823·Cancer Res·2007
7-preclinical
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors.
PMID 16857813·Clin Cancer Res·2006
6-review
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
PMID 16906227·J Clin Invest·2006
7-preclinical
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
PMID 16847462·Nat Rev Genet·2006
6-review
Factors predicting response to EGFR tyrosine kinase inhibitors.
PMID 16052433·Semin Respir Crit Care Med·2005
6-review
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
PMID 15731348·Proc Natl Acad Sci U S A·2005
7-preclinical
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
PMID 19447865·Clin Cancer Res·2009
7-preclinical
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
PMID 19106609·Cell Cycle·2009
6-review
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PMID 19237633·J Clin Oncol·2009
8-other
Modeling oncogene addiction using RNA interference.
PMID 18711136·Proc Natl Acad Sci U S A·2008
8-other
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
PMID 19029981·Nat Med·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 7600 OLD DOMINION COURT
APTOS, CA 95003 - Phone
- (831) 458-6200
Quick Facts
- NPI
- 1518963982
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile